Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments
(Bloomberg) -- Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that's already been cleared for use in the U.K.
While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck's showed a 50% reduction, “we can't yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.
Here are a few facts that we can put side-by-side until the data are analyzed further:
| Pfizer's Paxlovid | Merck's molnupiravir/Lagevrio | |
|---|---|---|
| Dosage | Twice daily for five days | Twice daily for five days |
| Production | Expects to make 180,000 packs by end of year and at least 50 million packs by end of 2022 | Expects to produce 10 million courses by end of the year, has licensed to generic-drug firms, and planning production increases |
| Regulatory status | Plans to add clinical data to rolling U.S. application for authorization | Approved in the U.K., submitted for U.S. authorization |
| Mechanism of action | protease inhibitor | viral mutagenic |
| SOURCE: | Company data |
EXPLAINER: Why New Pills to Treat Covid Could Be Game Changers
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.